Zacks Investment Research upgraded shares of Axonics (NASDAQ:AXNX – Get Rating) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Axonics Modulation Technologies Inc. is focused on development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction […]
Axonics (NASDAQ:AXNX – Get Rating) and Pulmonx (NASDAQ:LUNG – Get Rating) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations and institutional ownership. Profitability This table compares Axonics and Pulmonx’s net margins, return on equity […]
Axonics, Inc. (NASDAQ:AXNX – Get Rating) CEO Raymond W. Cohen sold 50,000 shares of the firm’s stock in a transaction on Monday, March 14th. The stock was sold at an average price of $52.82, for a total value of $2,641,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which […]
California State Teachers Retirement System trimmed its position in shares of Axonics, Inc. (NASDAQ:AXNX – Get Rating) by 8.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,630 shares of the company’s stock after selling 4,726 shares during the […]